Synonyms: compound B [WO2022002018A1] | LY-3499446
Compound class:
Synthetic organic
Comment: LY3499446 is a direct inhibitor of oncogenic KRAS mutant G12C that was developed for anticancer potential [1].
|
|
No information available. |
Summary of Clinical Use ![]() |
LY3499446 entered early stage clinical evaluation, but the study was terminated due to unexpected toxic effects that precluded further development. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04165031 | A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation | Phase 1/Phase 2 Interventional | Eli Lilly and Company |